Another group demonstrated that targeting CXCR4 and PD-1 concurrently showed promise in murine models, with the combination regimen leading to decreased MDSC infiltration and improved CD4/CD8 T cell ratios in the tumor [234]. Here, CD4 is linked to neoplasm.